Cargando…
Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab
Chronic lymphocytic leukaemia (CLL) is one of the most common haematological malignancies worldwide, with an increasing prevalence in the elderly population. Obinutuzumab is a type II anti-CD20 monoclonal antibody which showed superiority over rituximab in combination chemotherapy with chlorambucil...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SMC Media Srl
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346921/ https://www.ncbi.nlm.nih.gov/pubmed/30755907 http://dx.doi.org/10.12890/2016_000516 |